These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 619476)

  • 21. Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy.
    Samojlik E; Santen RJ; Worgul TJ
    Clin Endocrinol (Oxf); 1984 Jan; 20(1):43-51. PubMed ID: 6692582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma estrone-sulfate: assessment of reduced estrogen production during treatment of metastatic breast carcinoma.
    Samojlik E; Santen RJ; Worgul TJ
    Steroids; 1982 May; 39(5):497-507. PubMed ID: 6293125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
    Santen RJ; Santner SJ; Tilsen-Mallett N; Rosen HR; Samojlik E; Veldhuis JD
    Cancer Res; 1982 Aug; 42(8 Suppl):3353s-3359s. PubMed ID: 7083200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adrenal suppression with aminoglutethimide. I. Differential e-fects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone.
    Santen RJ; Wells SA; Runić S; Gupta C; Kendall J; Rudy EB; Samojlik E
    J Clin Endocrinol Metab; 1977 Sep; 45(3):469-79. PubMed ID: 198423
    [No Abstract]   [Full Text] [Related]  

  • 25. Resistance of the ovary to blockade of aromatization with aminoglutethimide.
    Santen RJ; Samojlik E; Wells SA
    J Clin Endocrinol Metab; 1980 Sep; 51(3):473-7. PubMed ID: 6773974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of plasma androgen and estrogen concentrations in ferrets with hyperadrenocorticism.
    Rosenthal KL; Peterson ME
    J Am Vet Med Assoc; 1996 Sep; 209(6):1097-102. PubMed ID: 8800255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
    Alexieva-Figusch J; de Jong FH; Lamberts WJ; van Gilse HA; Klign JG
    Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
    Santen RJ; Worgul TJ; Samojlik E; Boucher AE; Lipton A; Harvey H
    Cancer Res; 1982 Aug; 42(8 Suppl):3397s-3401s. PubMed ID: 7083205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer.
    Bruning PF; Bonfrer JM; De Jong-Bakker M; Nooyen W
    J Steroid Biochem; 1984 Sep; 21(3):293-8. PubMed ID: 6092781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chemical adrenalectomy induced by aminoglutethimide in the treatment of breast cancer. A review].
    Cikes M
    Schweiz Med Wochenschr; 1983 Mar; 113(11):382-91. PubMed ID: 6342129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical adrenalectomy in patients with advanced breast cancer.
    Horsley JS; Newsome HH; Brown PW; Neifeld JP; Terz JJ; Lawrence W
    Cancer; 1982 Mar; 49(6):1145-9. PubMed ID: 7059940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adrenal function under long-term raloxifene administration.
    Genazzani AR; Lombardi I; Borgioli G; di Bono I; Casarosa E; Gambacciani M; Palumbo M; Genazzani AD; Luisi M
    Gynecol Endocrinol; 2003 Apr; 17(2):159-68. PubMed ID: 12737677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
    Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
    Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The use of aminoglutethimide in the treatment of metastatic breast cancer].
    Bellora MG; Ciancio A; Ferrero A; Bergamino T; Zola P; Sismondi P
    Minerva Ginecol; 1991 Dec; 43(12):589-93. PubMed ID: 1819778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical adrenalectomy may replace surgery for advanced breast cancer.
    Check WA
    JAMA; 1980 Jul; 244(1):9-10. PubMed ID: 7382065
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
    Santen RJ; Boucher AE; Santner SJ; Henderson IC; Harvey H; Lipton A
    J Lab Clin Med; 1987 Mar; 109(3):278-89. PubMed ID: 3546561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is aminoglutethimide an alternative to adrenalectomy for metastatic carcinoma of the breast?
    Sterns EE; Bird CE; Mackie KW
    Can J Surg; 1982 Nov; 25(6):695-7. PubMed ID: 7139430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adrenal of male dog secretes androgens and estrogens.
    Santen RJ; Samojlik E; Demers L; Badder E
    Am J Physiol; 1980 Aug; 239(2):E109-12. PubMed ID: 7406039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
    Harris AL; Dowsett M; Smith IE; Jeffcoate S
    Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
    Geisler J; Haynes B; Anker G; Helle H; Ekse D; Dowsett M; Lønning PE
    J Steroid Biochem Mol Biol; 2005 Sep; 96(5):415-22. PubMed ID: 16168635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.